Importantly, the developed HER2 minibinder provides a promising foundation for future applications in breast cancer therapy, either as a direct therapeutic molecule or as a modular recognition domain for next-generation CAR T-cell engineering. The gene discussed is ERBB2; the disease is breast cancer.